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ABSTRACT
Galiellalactone (GL) is a fungal metabolite that presents antitumor activities on 
prostate cancer in vitro and in vivo. In this study we show that GL induced cell cycle 
arrest in G2/M phase, caspase-dependent apoptosis and also affected the microtubule 
organization and migration ability in DU145 cells. GL did not induce double strand 
DNA break but activated the ATR and ATM-mediated DNA damage response (DDR) 
inducing CHK1, H2AX phosphorylation (fH2AX) and CDC25C downregulation. 
Inhibition of the ATM/ATR activation with caffeine reverted GL-induced G2/M cell cycle 
arrest, apoptosis and DNA damage measured by fH2AX. In contrast, UCN-01, a CHK1 
inhibitor, prevented GL-induced cell cycle arrest but enhanced apoptosis in DU145 
cells. Furthermore, we found that GL did not increase the levels of intracellular ROS, 
but the antioxidant N-acetylcysteine (NAC) completely prevented the effects of GL on 
fH2AX, G2/M cell cycle arrest and apoptosis. In contrast to NAC, other antioxidants 
such as ambroxol and EGCG did not interfere with the activity of GL on cell cycle. GL 
significantly suppressed DU145 xenograft growth in vivo and induced the expression 
of fH2AX in the tumors. These findings identify for the first time that GL activates 
DDR in prostate cancer.
INTRODUCTION
Prostate cancer is the second most common 
diagnosed cancer in men worldwide and the first in 
developed countries. It has been estimated that 1.1 
million new cases have occurred in 2012 [1]. Initially, 
prostate cancer depends on androgens for growth, and 
androgen deprivation therapy (ADT) is effective in the 
early stages of the disease. However, 18-24 months later, 
the majority of patients does not respond to ADT and 
develop a castration-resistant prostate cancer (CRPC), 
which is associated with a poor prognosis, and mean 
survival [2–5].
STAT3 belongs to the signal transducers 
and activators of transcription (STATs) family of 
transcription factors. STAT3 is activated in response 
to several growth factors and cytokines and is 
involved in numerous physiological processes such as 
inflammation, cell growth and differentiation. However, 
constitutive activation of STAT3 has been observed 
in many tumor types, including prostate cancer [6–9]. 
STAT3 regulates the expression of cell-cycle regulators, 
angiogenic factors and anti-apoptotic genes, promoting 
tumorigenesis [10].
Microtubules are essential components of the 
cytoskeleton and play a key role in division, growth 
and migration functions. Microtubule inhibitors (vinca 
alkaloids) or microtubule stabilizers (taxanes) have 
been among the most active chemotherapeutic drugs in 
treating human cancer [11]. Several studies have linked 
cytoplasmatic STAT3 with cytoskeletal structures. For 
example, cytoplasmatic STAT3 may modulate microtubule 
dynamics and cell migration through a direct interaction 
with stathmin protein that is a tubuling-binding protein 
involved in the control of microtubule assembly and 
dynamics. [12, 13]. Also, STAT3 inhibition decreases 
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the migration of ovarian cancer cells and keratinocytes 
[14, 15]. Altogether, this suggests that inhibiting STAT3 
activity may be an effective therapeutic strategy for 
cancer [16].
Galiellalactone (GL) is a fungal metabolite with 
potent antitumor and anti-inflammatory effects, isolated 
from Galiella rufa and it has also been produced 
synthetically [17]. GL is a direct inhibitor of STAT3 
that prevents the binding of the activated STAT3 
dimers to DNA binding sites without affecting tyrosine 
phosphorylation [18, 19]. GL is cytotoxic and induces 
apoptosis in androgen-insensitive prostate cancer cell 
lines and in prostate cancer stem cell-like cells. GL also 
inhibits tumor growth and early metastatic dissemination 
of prostate cancer in mice [20–22]. In addition, it has 
been demonstrated that GL inhibits NF-κB and TGF-β 
signaling, preventing the association of p65 with the 
importin α3 and inhibiting the binding of the activated 
Smad2/3 transcription factor to DNA, respectively [23, 
24]. Also, GL improves experimental allergic asthma and 
it has an anti-thrombotic effect in murine models [25, 26].
In normal cells, the cell division cycle and apoptosis 
are tightly controlled, while cancer cells are characterized 
by deregulation in these processes [27, 28]. Checkpoints 
are the most important machinery involved in the control 
of the cell cycle. In response to genotoxic stress, DNA 
damage response (DDR) signaling pathway is activated, 
causing cell cycle arrest to allow the correction of the 
damage and to maintain genomic integrity. Checkpoints 
together with DNA repairing mechanisms and apoptosis 
are integrated in a circuitry that determines the ultimate 
response of a cell to DNA damage [29]. DNA damage is 
detected by MNR (MRE11, NBS1 and Rad50 proteins) 
and RPA (Human replication protein A) complexes act as 
sensors and recruit ataxia-telangiectasia mutated (ATM) 
and ataxia-telangiectasia and RAD3 related (ATR) to the 
site of the lesion, resulting in increased phosphorylation 
of histone H2AX (γH2AX), which is a marker of DNA 
damage. Activated ATM/ATR triggers phosphorylation 
of its downstream targets p53, CHK1 and CHK2, which 
in turn inhibit CDC25 phosphatases, preventing the 
activation of CDK1/Cyclin B and leading to G2/M arrest 
and initiation of DNA repair [30, 31]. Widely used drugs 
in cancer chemotherapy such as etoposide, cisplatin 
or doxorubicin are inducers of DNA damage pathway 
[32–34]. Therefore, the search for new effective drugs 
whose therapeutic target is ATM/ATR signaling may be a 
promising approach for CRPC treatment.
Natural products that induce cell cycle arrest and 
apoptosis have been an interesting source for the discovery 
of new therapeutic agents against cancer, including CRPC 
[35–37]. Our results provide first evidence that GL 
induces microtubules destabilization, DNA damage, G2/M 
cell cycle arrest and apoptosis through activation of the 
ATM/ATR pathway in the androgen-insensitive DU145 
cells. Moreover, GL was able to induce the expression 
of γH2AX in DU145 xenograft tumors and therefore its 
antitumor effects may be due to the activation of DNA 
damage pathway by the same mechanism that occurs 
in vitro.
RESULTS
Galiellalactone induces cell cycle arrest and 
apoptosis in DU145 cells
Since GL inhibits both STAT3 and NF-κB 
transcriptional activities, and both transcription factors 
participated in the progression of cell cycle in cancer cells 
[6, 38, 39], we were interested in studying the effect of 
GL on the cell cycle of prostate cancer cells. DU145 cells 
were treated with increasing concentrations of GL for 6, 
12 and 24 h and the percentage of cells in the different 
phases of cell cycle identified by FACS analysis. We show 
in Figure 1A and 1B that GL induced a dose-dependent 
cell cycle arrest in the G2/M phase that was more evident 
after 24 h of treatment in DU145 cells. Similar results 
were obtained in other human cancer cells like Jurkat or 
SK-N-SH (data not shown), and human prostate cancer 
cell line PC3 (Supplementary Figure 1). The different p53 
expression between the cell lines analyzed (p53 wild-type 
and null) indicated that GL induces G2/M phase cell cycle 
arrest independent of p53. In the same sense, PC3 cells 
(p53 null) transfected to express p53 wild-type showed 
analogous effects in response to GL (Supplementary Figure 
1). In contrast, GL did not induce cell cycle arrest either in 
primary fibroblasts or in non-tumorigenic RWPE-1 cells 
that are derived from prostate epithelium (Figure 1C).
Previous reports have shown that GL induces 
apoptosis in DU145 cells through a caspase-3 dependent 
pathway [20]. Thus, we investigated whether cell cycle 
arrest paralleled with caspase-3 activation and apoptosis. 
DU145 cells were pre-incubated with the cell-permeant 
pan caspase inhibitor Z-Vad-FMK and treated with GL. 
We found that GL induced the activation and cleavage of 
caspase-3 that preceded the membrane translocation of 
phosphatidyl-serine measured by Anexin-V staining and 
both activities were completely inhibited in the presence 
of Z-Vad-FMK (Figures 2A and 2B). On the contrary, pan 
caspase inhibitor did not prevent GL-induced G2/M phase 
cell cycle arrest (Figure 2C). These results indicate that 
GL affects different signaling pathways in DU145 cells, 
leading to cell cycle arrest and apoptosis.
Galiellalactone destabilizes microtubules and 
inhibits cell migration in DU145 cells
Actin and tubulins are abundant cytoskeletal proteins 
that support diverse cellular processes including cell cycle 
progression. To investigate the molecular and cellular 
mechanisms of GL effects on cell shape, we evaluated 
cell morphology using confocal microscopy, comparing 
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the effects induced by cytochalasin D, a blocker of actin 
polymerization and elongation of actin, with those induced 
by nocodazole and docetaxel, two antineoplasic agents 
that interfere microtubules polymerization.
We found that after 6 h GL produces a change in 
morphology, clearly reducing cell size to that observed 
in DU145 cells arrested in mitosis. Also, GL treatment 
does not cause aggregation of actin as observed after 
cytochalasin D treatment. However, GL was able to 
produce a similar microtubule destabilization observed 
with microtubule-targeting agents (MTAs) docetaxel and 
nocodazole (Figure 3A). MTAs but not GL induced an 
increase in the percentage of subdiploid cells (sub G0/G1) 
that corresponds to apoptotic cells after 24 h treatment, 
indicating that the action mechanism of MTAs and GL 
should be different (Figure 3B). Accordingly, subdiploid 
Figure 1: GL induces G2/M phase cell-cycle arrest. A. DU145 cells were exposed to various doses of GL (1, 10 and 20 μM) during 
6, 12 or 24 h and cell cycle was analyzed by PI staining and flow cytometry. Representative histograms are shown. B. Quantitation of 
percentages of the cells in each phase of the cell cycle. Data are the means of three independent experiments ± SD. *P<0.05; **P<0.01; 
***P<0.001 compared with the control group. C. Effect of GL (24 h) on cell cycle in human normal dermal fibroblasts and RWPE-1 cells. 
Representative histograms are shown.
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Figure 2: GL induction of cell-cycle arrest is mediated by a caspase-independent pathway. A. DU145 cells were treated 
with GL in the absence or the presence or the pan-caspase inhibitor Z-VAD-FMK (40 μM) for 48 h and protein expression of PARP and 
cleavaged caspase-3 was analyzed by immunoblot. B. DU145 cells were treated as above for 48 h, stained with Annexin V and PI and 
analyzed by flow cytometry. Representative plots and percentages are shown. C. DU145 cells were treated as in A and cell cycle distribution 
was determined by flow cytometry. Quantitation of percentages of the cells in each phase of the cell cycle. Data are the means of three 
independent experiments ± SD. ***P<0.001 compared with the control group.
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Figure 3: Effect of GL on cell morphology and cytoskeletal structure. A. Double immunofluorescent staining of actin (red) and 
α-tubulin (green) in DU145 cells treated with cytochalasin D (10 μM), GL (10 μM), nocodazole (100 ng/ml) and docetaxel (10 nM) for 6 h. 
The nuclei were counterstained with DAPI (blue). Cells were visualized by confocal microscopy (x63). B. Representative cell cycle profiles 
obtained by FACS at 24 h after the treatment with the indicated compounds.
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cells in GL-treated DU145 cells are detected only after 48 
h treatment (data not shown).
In order to evaluate if GL causes cell cycle arrest 
through de novo protein and RNA synthesis we used the 
transcriptional inhibitor mitomycin C. In the combined 
treatment we observed that cell cycle arrest produced 
by GL at 24 h was reversed with mitomycin C in DU145 
cells, indicating that cell cycle arrest at G2/M produced 
by GL requires de novo transcription of genes involved in 
cell cycle checkpoints regulation (Figure 4A). Recently, it 
has been shown that GL inhibits invasion in DU145 cells 
[22]. This finding, together with the effect on microtubules 
stabilization shown above, has led us to investigate the 
effects of GL on migration process by wound healing assay. 
We found that GL clearly impaired wound healing in DU145 
cells compared to untreated cells (Figures 4B and 4C).
GL activates ATM/ATR signaling pathway 
without induce massive DNA damage
To examine the molecular basis by which GL 
induces G2/M cell cycle arrest we firstly analyzed the 
expression of key proteins involved in cycle progression 
and checkpoint response. DU145 cells were stimulated 
with GL and the expression kinetic of the indicated 
proteins was analyzed. As shown in Figure 5A, the protein 
levels of pCDC25C (Ser216), CDC25C and pWee1 
(Ser642) were clearly down-regulated in a time-dependent 
manner in response to GL treatment. By contrast, other 
proteins such as Cyclin B1, pHistone H3 (Ser10) or p21 
were up-regulated. No significant change was observed in 
pCDK1 (Tyr15) and Myt1 expression levels, while Myt1 
hyperphosphorylation was clearly detected after 12 h of 
treatment. In summary, these results clearly indicate that 
GL may induce cell cycle arrest through the control of the 
expression of key proteins involved in the regulation of S 
and G2/M phases.
CDC25C is an essential protein for the control of 
the G2/M cell cycle transition, and also a key component 
of the checkpoint pathways that become activated in 
response to DNA damage or environmental insults. 
Under this stress situation, ATM and ATR kinases 
and their downstream checkpoint kinases CHK1 and 
CHK2, mediate the inhibition and/or degradation of 
CDC25C. Based on the ability of GL to mediate CDC25C 
degradation, we decided to analyze whether GL may 
activate the ATM/ATR pathway. To study this possibility, 
we first monitored CHK1 and CHK2 activation levels 
by analyzing the phosphorylation at Ser345 and Thr68, 
respectively. We show in Figure 5B that GL treatment led 
to CHK1 phosphorylation in a dose-dependent manner, 
not affecting the phosphorylation levels of CHK2. CHK1 
activation correlated with phosphorylation of CDC25C at 
the Ser216 site and posterior degradation. Similar results 
were obtained in PC3 cells (Supplementary Figure 2). 
These results indicate that GL-mediated down-regulation 
of CDC25C paralleled with CHK1 activation.
Next, to examine the capacity of GL to induce 
activation of DNA damage sensor kinases ATM/
ATR, DU145 cells were stimulated with GL and ATM 
Ser1981 and ATR Ser428 phosphorylation detected 
by immunoblotting. In parallel, we evaluated Ser139 
phosphorylation of histone H2A variant H2AX as marker 
of DNA damage. As shown in Figure 5C, GL induced ATM 
and ATR phosphorylation in a dose-dependent manner, 
affecting Ser139 phosphorylation levels of H2AX, with 
similar results were found in PC3 cells (Supplementary 
Figure 2). Finally, we performed a Comet-assay to 
determine DNA strand breaks (Figure 5D). In contrast 
to the analysis of γH2AX, no significant changes were 
observed in the cells stimulated with GL. By contrast, a 
dramatic Comet formation was observed under etoposide 
stimulation. These results demonstrate that GL mediates 
the activation of ATM/ATR signaling pathway without 
DNA double strand break.
Inhibition of ATM/ATR signaling pathway 
rescues GL-mediated G2/M phase cell-cycle 
arrest
In view of these results, we next examined the effect 
of ATM/ATR inhibitors on GL-mediated G2/M cell cycle 
arrest, DDR signaling pathway and apoptosis. DU145 
cells were stimulated with GL in the presence or absence 
of the CHK1/CHK2 dual inhibitor UCN-01, and cell cycle 
and the expression of pCHK1 (Ser345), γH2AX and PARP 
proteins evaluated in parallel. We found that inhibition of 
CHK1 prevented GL-mediated G2/M phase cell-cycle 
arrest (Figure 6A), but it did not interfere with GL-induced 
PARP cleavage (Figure 6B) and apoptosis, which was 
particularly increased (Figure 6C). Finally, and to further 
verify the role of ATM/ATR in GL-mediated G2/M cell 
cycle arrest, we performed similar experiments using the 
ATM/ATR inhibitor caffeine. DU145 cells stimulated 
with GL, in the absence or presence of caffeine, showed 
that ATM/ATR inhibition clearly rescued GL-mediated 
G2/M cell cycle arrest (Figure 6D), and prevented ATR, 
ATM and H2AX activation (Figure 6E). In contrast to the 
results obtained with CHK1/CHK2 inhibition, caffeine 
produced a significant reduction in GL-induced PARP 
cleavage and apoptosis (Figure 6F). Similarly, caffeine 
stimulation reverted GL capacity to impair wound healing 
in DU145 cells (Supplementary Figure 3). Altogether 
these data demonstrate that GL-mediated G2/M cell cycle 
arrest is mediated by activation of the ATM/ATR signaling 
pathway.
N-acetyl cysteine (NAC) suppresses cell cycle 
arrest and apoptosis produced by GL
The DDR cascade and ROS (reactive oxygen 
species) signaling are both involved in the induction of 
cell death after DNA damage. Thus, we were interested 
in investigating whether an increase of intracellular ROS 
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was involved in GL-induction of G2/M cell cycle arrest 
and apoptosis in DU145 cells. We show in Figure 7A 
that, in contrast to tert-butyl hydroperoxide (TBHP), GL 
was not able to increase the levels of intracellular ROS. 
Accordingly, neither the antioxidants ambroxol nor 
epigallocatechin gallate (EGCG) prevented GL-induced 
G2/M cell cycle arrest (Figure 7B). Interestingly, N-acetyl 
cysteine (NAC) treatment prevented the effect of GL on 
G2/M cell cycle arrest (Figure 7B), PARP cleavage, H2AX 
phosphorylation (Figure 7C) and apoptosis (Figure 7D). 
NAC is a scavenger of oxygen free radicals and a 
precursor of L-cysteine. GL has the ability to modify and 
covalently bind to cysteines, at least in the STAT3 protein, 
and therefore it is possible that NAC could bind GL 
attenuating its apoptotic effects.
In vivo effect of GL on H2AX phosphorylation in 
cancer prostate
Previous studies have demonstrated that GL 
produces a decrease tumor growth in several animal 
models of prostate cancer [20, 22]. Therefore, next we 
were interested in studying DDR after GL treatment 
in vivo. DU145 cell xenograft mouse model received 
a dose of 3 mg/kg through i.p injections every day 
for 21 days. Our results demonstrated that GL did not 
affect body weight of mice (Figure 8A). By contrast, a 
significant reduction of the volume tumor was observed 
during the treatment (Figure 8B) and the tumor 
weight was also significantly decreased after 21 days 
of GL treatment in comparison with untreated group 
Figure 4: GL inhibits cell motility. A. DU145 cells were pre-incubated with mitomycin C (5 μg/ml) for 1 h and treated with GL at 
10 and 20 μM for 24 h and cell cycle analyzed by PI staining and flow cytometry. Representative histograms are shown. B. DU145 cells 
were pre-incubated with mitomycin C (5 μg/ml) for 1 h, treated or not with GL at 10 μM for 24 h and relative wound density analyzed 
at different time points over a period of 24 h. The measurements are from wounds made on a monolayer of DU145 cells cultured in the 
presence of GL and control. Data are the means of three experiments ± SE. *P<0.05; **P<0.01 compared with the control group. C. Images 
of wound healing assay were obtained at 0, 12 or 24 h and the blue areas show the initial wound boundaries at 0 h.
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(Figure 8C). To investigate activation of DDR signaling 
pathway caused by GL we determined the expression of 
phosphorylated H2AX. Immunohistochemistry analysis 
of tissue sections showed that γH2AX positive cells 
expression was significantly higher in mice treated with 
GL in comparison with untreated mice (Figure 8D). These 
results confirm that activation of DNA damage signaling 
occurs in vitro and also in vivo.
Figure 5: Effect of GL on the expression of cell cycle proteins and DNA damage. A. Kinetic analysis on the steady state of 
proteins involved in G2/M phase. DU145 cells were treated with GL (10 μM) for the indicated times and the expression of the different 
proteins analyzed by western blots. B. Protein expression of pCHK1, pCHK2 and CDC25C and C. pATR, pATM, and γH2AX was 
evaluated by immunoblot in cells stimulated with GL for 24 h. D. Alkaline comet assay was performed to determine DNA fragments in 
DU145 cells treated with either GL (10 μM) or etoposide for 24 h. Representative images of alkaline comet assay and a graph with the tail 
moment are shown. ***P<0.001 compared with the control group.
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DISCUSSION
STAT3 and NF-κB have been identified to be 
involved in the processes of cell proliferation, cell 
differentiation and cell survival and, therefore, play 
an important role in tumorigenesis. In addition, it has 
been described that constitutive activation of these 
transcription factors contributes to chemoresistance in 
multiple malignancies [40]. On the other hand, it has 
been shown that EBV infection induces STAT3 activation 
that suppresses the DDR by interrupting ATR-CHK1 
signaling [41]. Moreover, STAT3 is required for efficient 
repair of damaged DNA following UVB irradiation and 
STAT3 deficient cells have reduced activity of ATM-
CHK1 pathway [42]. Also, it has been well-established 
that cytotoxic drugs and ionizing radiation activate 
NF-κB [40] involved in DNA repair mechanisms [43]. 
Therefore, NF-κB inhibitors administered in combination 
with cytostatic drugs enhanced the cytotoxicity activities 
of these treatments favoring pro-apoptotic cascade [44].
Figure 6: GL activates the ATM/ATR/CHK1 pathway. DU145 cells were pre-incubated for 1 h with either UCN-01 (1 μM) or 
caffeine (10 mM) and then treated with GL 10 μM for 24 h A, D. Representative cell cycle profiles obtained by flow cytometry at 24 h after 
the treatment with the indicated compounds. B, E. Identification of DNA damage (pCHK1 and γH2AX) and apoptotic (PARP) proteins. 
C, F. DU145 cells were treated as above for 48 h, stained with Annexin V and PI and analyzed by FACS. Percentages of Annexin V positive 
cells are shown. Data are the means of three experiments ± SD. *P<0.05; ***P<0.001 compared with the control group. #P< 0.05 compared 
with GL 10 μM group.
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It has been previously shown that GL is a dual 
NF-κB /STAT3 inhibitor, but nothing is known about its 
effects on cell cycle and DDR signaling in cancer cells. 
In this study, our results demonstrate that GL was able to 
induce cell cycle arrest at G2/M phase in human prostate 
cancer cell lines (DU145 and PC3), with similar results 
in other cancer cell lines like Jurkat and SK-N-SH (data 
not shown). Similarly, GL induces apoptosis in androgen-
insensitive prostate cancer cells through activation of 
ATM/ATR-CHK1 signaling without inducing DNA break. 
Thus, GL may exert antitumoral activity at different levels: 
inhibiting the action of the pro-survival transcription 
Figure 7: NAC inhibits GL-induced cell cycle arrest and apoptosis in DU145 cells. A. DU145 cells were treated with either 
GL or TBHP and the generation of intracellular ROS was determined with fluorescence probe DCFH2-DA. ***P<0.001 compared with the 
positive control group. B. DU145 cells were pre-incubated either NAC (1 mM), epigallocatechin (100 μM) or ambroxol (100 μM) followed 
by GL 10 μM treatment. Representative cell cycle profiles obtained by FACS after 24 h of treatment are shown. C. Protein expression of 
PARP, Caspase-3 and γH2AX was determined by western blot. D. DU145 cells were treated as above for 48 h, stained with Annexin V and 
PI and analyzed by FACS. Percentages of Annexin V positive cells are shown. Data are the means of triplicate experiments ± SD. **P<0.01 
compared with the control group. ##P< 0.01 compared with GL 10 μM group.
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factors STAT3/ NF-κB, inducing DNA damage signaling 
pathway and inhibiting DNA repairing mechanism 
(Figure 9). However, further studies are required to confirm 
that G2/M cell cycle arrest and activation of ATM/ATR-
signaling depend on these transcription factors.
Previous studies have shown that GL produces 
caspase-3 dependent apoptosis in prostate cancer cells 
[20, 21]. Treatment with Z-VAD-FMK, a pan caspase 
inhibitor, prevented apoptosis, corroborating previous 
results, although cell cycle arrest was maintained at G2/M 
in DU145 cells. These results demonstrate that a repair 
process is activated after GL in spite of blocking apoptosis 
cell death, showing that they are processes with different 
signaling pathways.
In some cases, such as after treatment with docetaxel 
or cytochalasin D, cell cycle arrest is accompanied 
by cytoskeleton disorganization at actin/tubulin levels 
[45–47]. Microtubule-targeting agents (MTAs) arrest 
mitosis and in turn cell death. Recently, an study have 
proposed that, instead of mitotic arrest, disrupting 
intracellular trafficking of DNA repair proteins (ATM, 
ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1 
and p63) is responsible of MTAs action mechanisms, such 
as vincristine or paclitaxel. Also, the treatment with these 
Figure 8: GL induces H2AX phosphorylation in prostate tumors. Athymic nude-Foxn1nu mice were injected subcutaneously with 
DU145 cells. After 4 weeks tumors were established and mice were treated every day during 21 days with GL (3 mg/kg) or DMSO (0.1%). 
A. Body weight in DU145 and GL-treated groups. B. Tumor volume (mm3) was evaluated every 3-4 days using a caliper. C. Tumor weight. 
D. γH2AX expression in tumor sections of controls and GL-treated mice DU145. Representative images are shown (x40). Quantitation of 
γH2AX positive cells/HPF (high power field) as shown in the graph. *P<0.05 compared with DU145 group.
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MTAs results in higher and sustained γ H2AX levels in 
A549 and MCF7 cells treated with radiation or etoposide. 
For this reason, the combination of MTAs plus DNA 
damaging agents enhances their effect separately [48]. 
Our results show that GL treatment provokes microtubule 
alteration at early stages in DU145 cells and thus might be 
hindering the transport of proteins involved in repairing 
the process, promoting cell arrest in G2/M and apoptosis.
Besides the ability to inhibit NF-κB/STAT3, we 
show that GL may target cancer cell progression by 
the activation of ATM/ATR pathway, inducing a rapid 
CDC25C degradation in DU145 cells. CDC25C protein 
stability is regulated by DDR kinases ATM/ATR-CHK1/
CHK2. We identified that GL activates DDR in DU145 
cells through ATR and ATM phosphorylation, which 
increases CHK1 phosphorylation at Ser345 but not 
phosphorylation of CHK2 at Thr68. Depending on the 
cellular context and DNA damage agents, ATM and ATR 
or both kinases may be activated. For example, whereas 
VP-16 provokes ATR activation [49], camptothecin 
activates either ATM or ATR in DNA damage events in 
different cancer cell lines [50]. The critical role of ATM/
ATR-CHK1 in the regulation of GL-mediated degradation 
of CDC25C was confirmed by the inhibition of the ATM/
ATR-CHK1 checkpoint control pathway using caffeine 
and the CHK1 inhibitor UCN-01.
ATM/ATR pathway is activated mainly in response 
to different types of DNA damage. Although we observed 
an increase in γH2AX levels in GL treated DU145 cells 
and animal models, GL did not induce massive DNA 
DSBs as compared with etoposide in comet assays. One 
possibility is that GL could be causing another type 
of DNA damage similar to that caused by alkylating 
agents, transferring methyl or ethyl group to a DNA 
base. The capacity of GL to covalently bind to cysteine 
could block the active cysteine site of O6-methylguanine 
methyltransferase (MGMT), inhibiting this protein 
and therefore preventing this DNA repair mechanism, 
activating DNA response signaling. DNA alkylating 
agents such as temozolomide, carmustine and estramustine 
Figure 9: Schematic model for the ability of GL to induce cell cycle arrest and apoptosis. GL induces DNA damage and 
activation of pATM/ATR, which phosphorylates H2AX and CHK1 to induce cell cycle arrest at the G2/M phase by CDC25C inhibition. 
Activation of pATM/ATR also induces apoptosis through a CHK1-independent pathway.
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are used in cancer therapy [51]. On the other hand, it 
has been reported that oxidative stress can also activate 
ATM by a mechanism independent of DNA DSBs [52]. 
In this sense, we show that GL does not produce ROS in 
DU145 cells but their effects on cell cycle and apoptosis 
were blocked with NAC treatment. NAC is an aminothiol 
used as an antioxidant, but it is also a synthetic precursor 
of GSH and intracellular cysteine, and can interact with 
proteins presenting cysteine residues or thiol groups [53, 
54]. In this context, a previous study showed that GL is a 
cysteine reactive inhibitor that covalently binds to cysteine 
in STAT3 inhibiting its binding to DNA. Therefore, while 
NAC could block the reactive site of GL, we cannot 
exclude oxidative stress to be involved in GL-mediated 
activation of ATM/ATR pathway.
In summary, this study reports for the first time a new 
mechanism of action for GL, with important consequences 
on the damage response pathway in the context of its 
antitumor activities on prostate cancer. We demonstrate how 
fungal GL induces DDR via ATM/ATR-CHK1 pathway, 
causing apoptosis and G2/M cell cycle arrest in prostate 
cancer (Figure 9), inhibiting tumor growth in vivo in mouse 
tumor models. These findings validate GL as a promising 
antitumor agent for treatment of castration-resistant prostate 
cancer, alone or in combination with other drugs.
MATERIALS AND METHODS
Cell culture and reagents
DU145, PC3 and RWPE-1 cells were from the 
American Type Culture Collection (ATCC, Manassas, 
VA, USA). DU145 and PC3 cells were cultured in RPMI 
1640 medium supplemented with 10% of fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. RWPE-1 
cells were cultured in keratinocyte serum free medium 
supplemented with bovine pituitary extract (0.05 mg/ml) 
and human recombinant epidermal growth factor (5 ng/
ml). Human normal dermal fibroblasts (HNDFs) were 
purchased to Innoprot (Bizkaia, Spain) and cultured in 
DMEM medium supplemented with 10% of FBS and 
antibiotics. Cells were incubated at 37ºC in a humidified 
atmosphere containing 5% CO2. Cell lines were routinely 
tested to be free of mycoplasma and cross contamination. 
DU145 validation was performed by a multiplex PCR 
with Geneprint10 System (Promega, Madison, WI, USA) 
following the manufacturer's manual. Galiellalactone 
was isolated as previously described [55] or purchased 
from US Biological Life Sciences (Salem, MA, USA). 
Mitomycin C and Z-VAD-FMK were obtained from Enzo 
Life Technologies (Farmingdale, NY, USA). Antibodies 
against anti-phospho-ATM Ser1981 [(D6H9)-5883], anti-
phospho-ATR Ser428 (2853), anti-phospho-CDC2 Tyr15 
(9111), anti-Cyclin B1 (4138), anti-phospho-Histone H3 
Ser10 [(D2C8)-3377], anti-Myt1 (4282), anti-phospho-
WEE1 Ser642 [(D47G5)-4910], anti-p21 Waf1/Cip1 
[(12D1)-2947], anti-phospho-CDC25C Ser216 (9528), 
anti-CDC25C [(5H9)-4688], anti-phospho-CHK2 Thr68 
[(C13C1)-2197], anti-phospho-CHK1 Ser345 [(133D3)-
2348], anti-PARP (9542), anti-Caspase-3 [(8G10)-9665], 
anti-phospho-Histone H2AX Ser139 [(20E3)-9718], 
anti-ATM [(D2E2)-2873], anti-ATR [(E1S3S)-13934], 
anti-CHK1 [(2G1D5)-2360] were purchased from Cell 
Signaling Technology (Danvers, MA, USA). The antibody 
anti-CHK2 (05-649) was obtained from Millipore (Merck 
Millipore, Billerica, MA, USA). The antibody anti-α-
Tubulin (T9026) and anti-Flag (F3165) were obtained 
from Sigma-Aldrich (St Louis, MO, USA). The antibody 
anti-p53 was obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Alexa Fluor 488 was purchased 
from Life Technologies (Carlsbad, CA, USA). All other 
reagents were from Sigma Co (St Louis, MO, USA).
FACS analysis
For cell cycle analysis, cells were fixed in 70% cold 
ethanol at -20ºC overnight. After that cells were washed 
with PBS once and then stained with 1 mg/mL propidium 
iodide (PI) and treated with RNase A (50 U/mL) for 2 h 
at 37ºC in darkness. For apoptosis studies, cells were 
harvested and washed in cold PBS and then resuspended 
in binding buffer consisting of 10 mM Hepes, 140 mM 
NaCl and 2.5 mM CaCl2 pH 7.4. Cells were stained with 
Annexin V, Alexa Fluor 488 conjugate (Molecular Probes 
by life technologies, Carlsbad, CA, USA) and propidium 
iodide. Cell cycle distribution and apoptosis were 
determined by BD FACSCanto™ flow cytometer (BD 
Biosciences, San Jose, CA, USA) using BD FACSDiva™ 
software.
Western blotting
Whole cell extracts were obtained by lysing the cells 
in NP-40 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
10% glycerol and 1% NP-40) supplemented with protease 
and phosphatase inhibitors. Lysate concentrations were 
determined by the Bradford assay (Bio-Rad Laboratories, 
Hercules, CA, USA). Proteins (50 μg/lane) were separated 
by SDS-PAGE, transferred onto PVDF membranes and 
blocked with PBS-T (Phosphate-buffered saline and 
0.1% Tween-20) containing 5% non-fat dry milk for 
1 h at room temperature (RT). Incubation with primary 
antibodies was performed overnight at 4ºC, followed by 
incubation with the appropriate horseradish peroxidase-
conjugated secondary antibody. The washed membranes 
were incubated with appropriate secondary antibodies 
coupled to horseradish peroxidase that were detected by 
an enhanced chemiluminescent reagent (ECL).
Immunofluorescence
DU145 cells were grown on coverslips and after 
treatment fixed for 20 min in 4% paraformaldehyde and 
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permeabilized in 0.12% Triton X-100 for 10 min. After 
that, cells were stained for 1 h at room temperature 
with Phalloidin-TRITC 10 μg/mL and anti-α-Tubulin 
(T9026) for staining of actin filaments and microtubules, 
respectively, and counterstained with Alexa Fluor 488 
goat-anti-mouse IgG secondary antibody. Coverslides 
were mounted in Vectashield mounting media with 
DAPI (Vector Laboratories Inc., Burlingame, CA, 
USA) and examined with an LSM 5 EXCITER (Carl 
Zeiss MicroImaging GmbH) confocal laser-scanning 
microscope using a 63×/1.40 oil objective (Plan-
Apochromat), and ZEN 2008 software (Carl Zeiss 
MicroImaging GmbH).
Measurement of ROS levels
Cells were stimulated with either GL or tert-butyl 
hydroperoxide (TBHP) (0.4 mM). After 3 h of incubation, 
cells were washed with PBS and incubated with 1 μM of 
2,7-dichlorofluorescein diacetate (H2DCF-DA; Molecular 
Probes, OR, USA) for 20 min at 37ºC in darkness. 
Fluorescence was measured at 450 nm excitation and 
535 nm emission using a TECAN GENios Pro (Tecan 
Group Ltd, Switzerland).
Wound healing assay
DU145 cells were seeded on 96-well plates 
(ImageLock plate, Essen Bioscience, Ann Arbor, MI, 
USA) at a 5 × 104 cell density and were allowed to attach 
overnight. When cells reached confluence, a wound was 
scratched across each well using Wound Maker device 
(Essen Bioscience) and detached cells were removed by 
gentle washing with PBS. Then, cells were treated or not 
with GL in the presence of mitomycin C (5 μg/ml). Images 
have a blue mask showing the initial wound boundaries 
at 0 h and wound closure was monitored hourly for 24 h 
and quantified as wound confluence (%) with IncuCyte 
ZOOM Live-Cell Imaging System (Essen Bioscience, 
Hertfordshire, UK).
Comet assay
Cells (4 × 105) were seeded into 6-well plates and 
treated with GL or etoposide for 24 h. DNA damage 
was detected using an OxiSelect™ Comet Assay kit 
(Cell Biolabs Inc, San Diego, USA) following the 
manufacturer's instructions. Briefly, cells were harvested 
and mixed with low melt agarose on the OxiSelect Comet 
Slide. Then, the embedded cells were lysed and treated 
with alkaline solution to denature DNA. After that, 
electrophoresis was carried out under alkaline conditions 
at 1 V/cm and 300 mA for 30 min and the samples stained 
with Vista Green fluorescence dye for 15 min in darkness, 
analysed using a Leica DM2500 fluorescent microscope 
and quantified by Casp software (CASPlab, Wroclaw, 
Poland).
Prostate tumor xenograft model
Six-week-old male athymic nude-Foxn1nu mice 
(Harlan Laboratories, Barcelona, Spain) were kept on 
a 12 h light-dark cycle, temperature 20ºC (±2ºC) and 
40-50% relative humidity with free access to standard 
food and water. Experimental procedure was performed 
in accordance with European Union and the Córdoba 
University ethical committee guidelines (2014PI/015). 
A total of 10 mice were injected subcutaneously into the 
flank with 3x106 DU145 cells and tumors were established 
4 weeks after injection. Then, mice were divided into 
2 groups: Group 1 (n=5) received vehicle (1% DMSO in 
PBS) and group 2 (n=5) were treated with 3 mg/kg of GL 
by intraperitoneal injection (i.p) every day for 3 weeks in 
both cases. Tumor volume was measured every 3-4 days 
using a caliper and calculated by the formula length (mm) 
x width x height x 0.5632. After treatment, mice were 
sacrificed and tumours were extracted, weighted, fixed 
in 4% paraformaldehyde and then embedded in paraffin. 
Sections (5 μM thickness) of each tumour were prepared 
for immunohistochemistry analysis.
Immunohistochemistry
The sections of xenograft tumor samples were 
deparaffinized in xylene and rehydrated through a graded 
ethanol series ending in water. Antigen retrieval was done 
by heating in sodium citrate 10 mM pH 6 at 98ºC for 
10 min and then incubated in methanol and 0.3% hydrogen 
peroxide for 30 min to block endogenous peroxidase 
activity. Non-specific binding was blocked with IHC Select 
Blocking Reagent (Merck Millipore, Billerica, MA, USA) 
at room temperature for 30 min followed by incubation 
with the phospho-histone H2AX (Ser139) primary antibody 
at 4ºC overnight. After that, samples were incubated with 
secondary antibody goat anti-rabbit (Merck Millipore, 
Billerica, MA, USA) at room temperature for 4 h. 
Incubation with the IHC Select Streptavidin-HRP reagent 
was performed at room temperature for 30 min, before 
the chromogen was developed using diaminobenzidine 
according to the manufacturer's instructions (Merck 
Millipore, Billerica, MA, USA). A Leica DM2500 
microscope and a Leica DFC420c camera were used for 
slide observation and photography and all image processing 
was done using ImageJ (Bethesda. MD, USA).
Statistical analysis
Data are expressed as mean ± SD, except for wound 
healing assay, whose data are represented as mean ± SE. 
Animal studies are expressed as mean ± SEM. Differences 
were analyzed by one-way ANOVA test followed by 
Newman-Keuls post hoc test. P< 0.05 was considered 
statistically significant. Statistical analysis was performed 
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